Embolx Secures New CMS HCPCS Level II G-Code for Pressure-Generating Catheter Procedures Performed in the Physician Office (OBL)
Embolx Secures New CMS HCPCS Level II G-Code for Pressure-Generating Catheter Procedures Performed in the Physician Office (OBL)
PR Newswire
SUNNYVALE, Calif., July 13, 2026
New code, effective July 1, 2026, expands patient access to advanced embolization procedures at a lower-cost site of service
SUNNYVALE, Calif., July 13, 2026 /PRNewswire/ -- Embolx, Inc., a leader in advanced microcatheter technology for targeted embolization procedures, today announced that the Centers for Medicare & Medicaid Services (CMS) has established a new HCPCS Level II code, G0577, covering Sniper® procedures performed in the physician office, or office-based lab (OBL), setting. The new code took effect July 1, 2026.

Embolx led the effort to secure the new code for OBL procedures using the Sniper Balloon Occlusion Microcatheter, working in close collaboration with CMS over more than a year. Embolx is proud to have driven the initiative that created this new reimbursement pathway, which the company believes will improve patient access to pressure-generating catheter procedures in a lower-cost care setting.
"We are grateful to CMS for their collaboration throughout this process, and to our physician advisors, reimbursement consultants, attorneys and staff who guided us every step of the way," said Michael Allen, CEO of Embolx. "This new code expands access to pressure-generating catheters to a lower-cost site of service where patients receive high-quality care."
The new code reflects a broader shift toward performing interventional oncology procedures in office-based settings, where physicians say the combination of lower costs and streamlined logistics benefits patients without compromising quality of care.
"I congratulate Embolx for their efforts to expand essential care to the Office-Based Lab (OBL) setting," said Dr. Aaron Fischman, Professor of Interventional Radiology, Urology, and Surgery at Mount Sinai, New York. "Our center has utilized the Sniper microcatheter for years because it consistently improves clinical outcomes for our patients. The introduction of the new G-code, G0577, is a significant milestone that will further support the delivery of high-quality interventional oncology care".
Balloon occlusion pressure embolization is used in the treatment of primary liver cancer, prostate artery embolization, and other conditions.
About Embolx
Embolx, Inc. is a medical device company developing advanced microcatheter technologies for targeted embolization procedures, including its Sniper Balloon Occlusion Microcatheter. Embolx has pioneered advanced pressure-mediated delivery of therapeutics directly into cancerous tumors, prostates, and other anatomical structures and is dedicated to transforming healthcare through the development of innovative technologies.
Media Contact
Haley McGregor
Global Marketing and Sales Operations Manager
Embolx, Inc.
hmcgregor@embolx.com

SOURCE Embolx

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
3 Stocks to Sell and 3 Stocks to Buy for October
The Top Funds for a Simpler Retirement Portfolio
